Agenus AGM: Bot/Bal Combo Targets “Cold” MSS Colorectal Cancer as Phase III BATMAN Trial Launches

Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer

LEXINGTON, Mass.--(BUSINESS WIRE)--Apr 1, 2026-

Agenus enrols first patient in BATTMAN Phase III trial

Agenus has enrolled the first patient in the BATTMAN Phase III trial, assessing BOT plus BAL in refractory, unresectable MSS or pMMR mCRC.The post Agenus enrols first patient in BATTMAN Phase III trial appeared first on Clinical Trials Arena.

Agenus AGM: Bot/Bal Combo Targets “Cold” MSS Colorectal Cancer as Phase III BATMAN Trial Launches

Agenus (NASDAQ:AGEN) used its March stakeholder webcast to highlight progress for its investigational immunotherapy combination of botensilimab and balstilimab (bot/bal), emphasizing efforts to broaden immunotherapy’s reach into “cold” tumors such as microsatellite stable (MSS) metastatic colorectal cancer (mCRC), where conventional checkpoint inhibitors have historically shown limited benefit. Company frames MSS colorectal cancer as a key […]